All In Biotech

Drug Trial Radar · NCT00024167

Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer

A Prospective Randomized Phase III, Trial Comparing Consolidation Therapy With or Without Strontium-89 Following Induction Chemotherapy in Androgen-Independent Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Mar 22, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 265 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

265

Actual

Start

Apr 2002

Primary completion

Sep 2014

Sponsor

Lead sponsor
M.D. Anderson Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Jan 27, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radioactive substances such as strontium-89 may relieve bone pain associated with prostate cancer. It is not yet known whether chemotherapy is more effective with or without strontium-89 in treating bone metastases. PURPOSE: This randomized phase III trial is studying giving chemotherapy together with strontium-89 to see how well it works compared to chemotherapy alone in treating patients with prostate cancer that has spread to the bone.

Conditions

  • Prostate Cancer

Interventions

  • DocetaxelDrug

    75 mg/m2 intravenous piggyback (IVPB) over 1 hour, Day 1, every 3 weeks.

  • Doxorubicin hydrochlorideDrug

    20 mg/m2 IV, day 1 on Weeks 1, 3, 5

  • Estramustine phosphate sodiumDrug

    140 mg orally 3 x day, Days 1 through 7 on Weeks 2, 4, 6

  • KetoconazoleDrug

    400 mg orally (po) 3 x day, Days 1 through 7

  • PrednisoneDrug

    5 mg orally 2 x daily, weeks 1-14

  • VinblastineDrug

    4 mg/m2 IVPB, Day 1 on Weeks 2, 4, 6

  • Strontium chloride Sr 89Radiation

    One dose (4 mCi total dose) IV

  • DexamethasoneDrug

    4 mg is given orally at 12 and 1 hours before and 12 hours after docetaxel.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival From RandomizationTime frame: Followed every 4 weeks from randomization until death, up to 7 years.

Locations

40 sites in 1 country. Site status is shown where the registry gives one.

  • Northeast Georgia Medical Center

    Gainesville, Georgia

  • Curtis and Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center

    Savannah, Georgia

  • Veterans Affairs Medical Center - Hines

    Hines, Illinois

  • Swedish-American Regional Cancer Center

    Rockford, Illinois

  • Hematology Oncology Associates of the Quad Cities

    Bettendorf, Iowa

  • Genesis Regional Cancer Center at Genesis Medical Center

    Davenport, Iowa

  • Siouxland Hematology-Oncology Associates, LLP

    Sioux City, Iowa

  • Mercy Medical Center - Sioux City

    Sioux City, Iowa

  • St. Luke's Regional Medical Center

    Sioux City, Iowa

  • University of Mississippi Cancer Clinic

    Jackson, Mississippi

  • CCOP - Montana Cancer Consortium

    Billings, Montana

  • Hematology-Oncology Centers of the Northern Rockies - Billings

    Billings, Montana

  • Northern Rockies Radiation Oncology Center

    Billings, Montana

  • St. Vincent Healthcare Cancer Care Services

    Billings, Montana

  • Billings Clinic - Downtown

    Billings, Montana

  • Bozeman Deaconess Cancer Center

    Bozeman, Montana

  • St. James Healthcare Cancer Care

    Butte, Montana

  • Big Sky Oncology

    Great Falls, Montana

  • Great Falls Clinic - Main Facility

    Great Falls, Montana

  • Sletten Cancer Institute at Benefis Healthcare

    Great Falls, Montana

  • Site not named

    Great Falls, Montana

  • St. Peter's Hospital

    Helena, Montana

  • Glacier Oncology, PLLC

    Kalispell, Montana

  • Kalispell Medical Oncology at KRMC

    Kalispell, Montana

  • Kalispell Regional Medical Center

    Kalispell, Montana

  • Community Medical Center

    Missoula, Montana

  • Guardian Oncology and Center for Wellness

    Missoula, Montana

  • Montana Cancer Specialists at Montana Cancer Center

    Missoula, Montana

  • Montana Cancer Center at St. Patrick Hospital and Health Sciences Center

    Missoula, Montana

  • Good Samaritan Cancer Center at Good Samaritan Hospital

    Kearney, Nebraska

  • Kinston Medical Specialists

    Kinston, North Carolina

  • Summa Center for Cancer Care at Akron City Hospital

    Akron, Ohio

  • Barberton Citizens Hospital

    Barberton, Ohio

  • Cancer Care Center, Incorporated

    Salem, Ohio

  • Cancer Treatment Center

    Wooster, Ohio

  • McLeod Regional Medical Center

    Florence, South Carolina

  • CCOP - Greenville

    Greenville, South Carolina

  • Medical City Dallas Hospital

    Dallas, Texas

  • University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Welch Cancer Center at Sheridan Memorial Hospital

    Sheridan, Wyoming

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.